View ValuationHualan Biological Engineering 향후 성장Future 기준 점검 1/6Hualan Biological Engineering (는) 각각 연간 18.1% 및 7.8% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 16.5% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 9.7% 로 예상됩니다.핵심 정보18.1%이익 성장률16.53%EPS 성장률Biotechs 이익 성장29.7%매출 성장률7.8%향후 자기자본이익률9.66%애널리스트 커버리지Good마지막 업데이트07 May 2026최근 향후 성장 업데이트업데이트 없음모든 업데이트 보기Recent updates공고 • Jun 30Hualan Biological Engineering Inc. to Report First Half, 2026 Results on Aug 29, 2026Hualan Biological Engineering Inc. announced that they will report first half, 2026 results on Aug 29, 2026Declared Dividend • Jun 11Dividend of CN¥0.50 announcedShareholders will receive a dividend of CN¥0.50. Ex-date: 15th June 2026 Payment date: 15th June 2026 Dividend yield will be 7.6%, which is higher than the industry average of 1.6%. Sustainability & Growth Dividend is not covered by earnings (213% earnings payout ratio) nor is it covered by cash flows (270% cash payout ratio). The dividend has increased by an average of 23% per year over the past 10 years. However, payments have been volatile during that time. The company's earnings per share (EPS) would need to grow by 137% to bring the payout ratio under control. EPS is expected to grow by 65% over the next 3 years, which means the dividend may need to be reduced to reach a sustainable payout ratio.공고 • Jun 10Hualan Biological Engineering Inc. Announces 2025 Final Profit Distribution Plan to Be Implemented (A Shares), Payable on 15 June 2026Hualan Biological Engineering Inc. announced 2025 final profit distribution plan to be implemented (A shares) of CNY 5.00000000 per 10 shares(tax included). Record date: 12 June 2026, Ex-date: 15 June 2026, Payment date: 15 June 2026.Board Change • May 20Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was an independent director. The company's board is composed of: 1 new director. 6 experienced directors. 5 highly experienced directors. 3 independent directors (6 non-independent directors). Independent Director Zhiqian Zhang was the last independent director to join the board, commencing their role in 2025. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.공고 • Mar 31Hualan Biological Engineering Inc. to Report Q1, 2026 Results on Apr 27, 2026Hualan Biological Engineering Inc. announced that they will report Q1, 2026 results on Apr 27, 2026공고 • Mar 28Hualan Biological Engineering Inc., Annual General Meeting, Apr 20, 2026Hualan Biological Engineering Inc., Annual General Meeting, Apr 20, 2026, at 14:30 China Standard Time. Location: The Company's Meeting Room, Xinxiang, Henan China공고 • Dec 31Hualan Biological Engineering Inc. to Report Fiscal Year 2025 Results on Mar 28, 2026Hualan Biological Engineering Inc. announced that they will report fiscal year 2025 results on Mar 28, 2026공고 • Sep 30Hualan Biological Engineering Inc. to Report Q3, 2025 Results on Oct 30, 2025Hualan Biological Engineering Inc. announced that they will report Q3, 2025 results on Oct 30, 2025공고 • Sep 24Hualan Biological Engineering Inc. Approves Interim Dividend for 2025Hualan Biological Engineering Inc. held its 2nd Extraordinary General Meeting of 2025 on 22 September 2025, approved interim Cash dividend/10 shares (tax included): CNY5.00000000 for 2025.공고 • Aug 29Hualan Biological Engineering Inc. Proposes Interim Cash Dividend for 2025Hualan Biological Engineering Inc. at its EGM to be held on September 22, 2025, proposed the detailed profit distribution plan are as follows: Cash dividend/10 shares (tax included): CNY5.00000000.공고 • Jul 02Hualan Biological Engineering Inc. to Report First Half, 2025 Results on Aug 29, 2025Hualan Biological Engineering Inc. announced that they will report first half, 2025 results on Aug 29, 2025공고 • Apr 01Hualan Biological Engineering Inc. Proposes Final Cash Dividend for the Year 2024Hualan Biological Engineering Inc. announced on 31 March 2025 the profit distribution proposal for the year 2024 as final cash dividend/10 shares (tax included) of CNY 2.00000000.공고 • Mar 31Hualan Biological Engineering Inc. to Report Q1, 2025 Results on Apr 28, 2025Hualan Biological Engineering Inc. announced that they will report Q1, 2025 results on Apr 28, 2025공고 • Mar 29Hualan Biological Engineering Inc., Annual General Meeting, Apr 25, 2025Hualan Biological Engineering Inc., Annual General Meeting, Apr 25, 2025, at 14:30 China Standard Time. Location: The Company's Meeting Room, Xinxiang, Henan China공고 • Dec 31Hualan Biological Engineering Inc. to Report Fiscal Year 2024 Results on Mar 29, 2025Hualan Biological Engineering Inc. announced that they will report fiscal year 2024 results on Mar 29, 2025Reported Earnings • Oct 30Third quarter 2024 earnings released: EPS: CN¥0.27 (vs CN¥0.30 in 3Q 2023)Third quarter 2024 results: EPS: CN¥0.27 (down from CN¥0.30 in 3Q 2023). Revenue: CN¥1.84b (down 21% from 3Q 2023). Net income: CN¥483.5m (down 11% from 3Q 2023). Profit margin: 26% (up from 23% in 3Q 2023). The increase in margin was driven by lower expenses. Revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 26% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has fallen by 19% per year, which means it is performing significantly worse than earnings.공고 • Sep 30Hualan Biological Engineering Inc. to Report Q3, 2024 Results on Oct 31, 2024Hualan Biological Engineering Inc. announced that they will report Q3, 2024 results on Oct 31, 2024Valuation Update With 7 Day Price Move • Sep 27Investor sentiment improves as stock rises 16%After last week's 16% share price gain to CN¥16.41, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 21x in the Biotechs industry in China. Total loss to shareholders of 39% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥27.89 per share.Reported Earnings • Aug 30Second quarter 2024 earnings released: EPS: CN¥0.098 (vs CN¥0.096 in 2Q 2023)Second quarter 2024 results: EPS: CN¥0.098 (up from CN¥0.096 in 2Q 2023). Revenue: CN¥865.4m (up 23% from 2Q 2023). Net income: CN¥178.4m (up 2.0% from 2Q 2023). Profit margin: 21% (down from 25% in 2Q 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 24% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has fallen by 20% per year, which means it is performing significantly worse than earnings.공고 • Jun 29Hualan Biological Engineering Inc. to Report First Half, 2024 Results on Aug 30, 2024Hualan Biological Engineering Inc. announced that they will report first half, 2024 results on Aug 30, 2024Declared Dividend • Jun 08Dividend of CN¥0.30 announcedDividend of CN¥0.30 is the same as last year. Ex-date: 14th June 2024 Payment date: 14th June 2024 Dividend yield will be 1.7%, which is about the same as the industry average. Sustainability & Growth Dividend is covered by earnings (39% earnings payout ratio) but not covered by cash flows (159% cash payout ratio). The dividend has increased by an average of 25% per year over the past 10 years. However, payments have been volatile during that time. EPS is expected to grow by 62% over the next 3 years, which should provide support to the dividend and adequate earnings cover.공고 • Jun 08Hualan Biological Engineering Inc. Announces Final Profit Distribution Plan to Be Implemented on A Shares for the Year 2023, Payable on 14 June 2024Hualan Biological Engineering Inc. announced final profit distribution plan to be implemented on A shares as cash dividend per ten shares (tax included) of CNY 3.00000000 for the year 2023, payable on 14 June 2024. Record date: 13 June 2024. Ex-date: 14 June 2024.Reported Earnings • Apr 26First quarter 2024 earnings released: EPS: CN¥0.14 (vs CN¥0.19 in 1Q 2023)First quarter 2024 results: EPS: CN¥0.14 (down from CN¥0.19 in 1Q 2023). Revenue: CN¥787.3m (down 11% from 1Q 2023). Net income: CN¥261.8m (down 26% from 1Q 2023). Profit margin: 33% (down from 40% in 1Q 2023). Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has fallen by 23% per year, which means it is performing significantly worse than earnings.Reported Earnings • Apr 01Full year 2023 earnings released: EPS: CN¥0.81 (vs CN¥0.59 in FY 2022)Full year 2023 results: EPS: CN¥0.81 (up from CN¥0.59 in FY 2022). Revenue: CN¥5.34b (up 18% from FY 2022). Net income: CN¥1.48b (up 38% from FY 2022). Profit margin: 28% (up from 24% in FY 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 25% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has fallen by 11% per year but the company’s share price has fallen by 21% per year, which means it is performing significantly worse than earnings.공고 • Mar 30Hualan Biological Engineering Inc. to Report Q1, 2024 Results on Apr 26, 2024Hualan Biological Engineering Inc. announced that they will report Q1, 2024 results on Apr 26, 2024공고 • Dec 30Hualan Biological Engineering Inc. to Report Fiscal Year 2023 Results on Mar 30, 2024Hualan Biological Engineering Inc. announced that they will report fiscal year 2023 results on Mar 30, 2024Reported Earnings • Nov 01Third quarter 2023 earnings released: EPS: CN¥0.30 (vs CN¥0.17 in 3Q 2022)Third quarter 2023 results: EPS: CN¥0.30 (up from CN¥0.17 in 3Q 2022). Revenue: CN¥2.33b (up 86% from 3Q 2022). Net income: CN¥540.6m (up 70% from 3Q 2022). Profit margin: 23% (down from 25% in 3Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 24% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has fallen by 12% per year but the company’s share price has fallen by 20% per year, which means it is performing significantly worse than earnings.Reported Earnings • Aug 24Second quarter 2023 earnings released: EPS: CN¥0.096 (vs CN¥0.19 in 2Q 2022)Second quarter 2023 results: EPS: CN¥0.096 (down from CN¥0.19 in 2Q 2022). Revenue: CN¥704.6m (down 59% from 2Q 2022). Net income: CN¥175.0m (down 50% from 2Q 2022). Profit margin: 25% (up from 20% in 2Q 2022). The increase in margin was driven by lower expenses. Revenue is forecast to grow 23% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has fallen by 11% per year but the company’s share price has fallen by 29% per year, which means it is performing significantly worse than earnings.공고 • Jun 08Hualan Biological Engineering Inc. Announces Final Dividend on Share A for 2022, Payable on June 14, 2023Hualan Biological Engineering Inc. announced final Cash dividend/10 shares (tax included): CNY 3.00000000 on share A for 2022. Record date: 13 June 2023, Ex-date: 14 June 2023, Payment date: 14 June 2023.Reported Earnings • Mar 30Full year 2022 earnings released: EPS: CN¥0.59 (vs CN¥0.71 in FY 2021)Full year 2022 results: EPS: CN¥0.59 (down from CN¥0.71 in FY 2021). Revenue: CN¥4.52b (up 1.8% from FY 2021). Net income: CN¥1.08b (down 17% from FY 2021). Profit margin: 24% (down from 29% in FY 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 20% p.a. on average during the next 2 years, compared to a 24% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has fallen by 17% per year, which means it is performing significantly worse than earnings.Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Director Yunlong Wang was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Oct 31Third quarter 2022 earnings released: EPS: CN¥0.17 (vs CN¥0.33 in 3Q 2021)Third quarter 2022 results: EPS: CN¥0.17 (down from CN¥0.33 in 3Q 2021). Revenue: CN¥1.25b (down 40% from 3Q 2021). Net income: CN¥317.6m (down 47% from 3Q 2021). Profit margin: 25% (down from 29% in 3Q 2021). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has remained flat but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings.Reported Earnings • Aug 24Second quarter 2022 earnings released: EPS: CN¥0.19 (vs CN¥0.11 in 2Q 2021)Second quarter 2022 results: EPS: CN¥0.19 (up from CN¥0.11 in 2Q 2021). Revenue: CN¥1.71b (up 157% from 2Q 2021). Net income: CN¥349.1m (up 71% from 2Q 2021). Profit margin: 20% (down from 31% in 2Q 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to stay flat compared to a 34% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings.Valuation Update With 7 Day Price Move • Jun 21Investor sentiment improved over the past weekAfter last week's 19% share price gain to CN¥22.86, the stock trades at a forward P/E ratio of 26x. Average forward P/E is 30x in the Biotechs industry in China. Total returns to shareholders of 4.1% over the past three years.Board Change • May 25Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Director Yunlong Wang was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Apr 01Full year 2021 earnings released: EPS: CN¥0.71 (vs CN¥0.89 in FY 2020)Full year 2021 results: EPS: CN¥0.71 (down from CN¥0.89 in FY 2020). Revenue: CN¥4.44b (down 12% from FY 2020). Net income: CN¥1.30b (down 20% from FY 2020). Profit margin: 29% (down from 32% in FY 2020). The decrease in margin was driven by lower revenue. Over the next year, revenue is forecast to grow 9.4%, compared to a 51% growth forecast for the pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings.Valuation Update With 7 Day Price Move • Sep 08Investor sentiment deteriorated over the past weekAfter last week's 15% share price decline to CN¥30.13, the stock trades at a forward P/E ratio of 32x. Average forward P/E is 36x in the Biotechs industry in China. Total returns to shareholders of 71% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥17.49 per share.Reported Earnings • Aug 30Second quarter 2021 earnings released: EPS CN¥0.11 (vs CN¥0.14 in 2Q 2020)The company reported a poor second quarter result with weaker earnings, revenues and profit margins. Second quarter 2021 results: Revenue: CN¥665.2m (down 6.2% from 2Q 2020). Net income: CN¥204.5m (down 23% from 2Q 2020). Profit margin: 31% (down from 37% in 2Q 2020). The decrease in margin was primarily driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 17% per year whereas the company’s share price has increased by 21% per year.Reported Earnings • May 02First quarter 2021 earnings released: EPS CN¥0.14 (vs CN¥0.14 in 1Q 2020)The company reported a decent first quarter result with improved earnings and profit margins, although revenues were weaker. First quarter 2021 results: Revenue: CN¥623.4m (down 8.0% from 1Q 2020). Net income: CN¥252.8m (up 2.2% from 1Q 2020). Profit margin: 41% (up from 37% in 1Q 2020). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has increased by 40% per year, which means it is tracking significantly ahead of earnings growth.Reported Earnings • Mar 31Full year 2020 earnings released: EPS CN¥0.89 (vs CN¥0.71 in FY 2019)The company reported a solid full year result with improved earnings and revenues, although profit margins were weaker. Full year 2020 results: Revenue: CN¥5.02b (up 36% from FY 2019). Net income: CN¥1.61b (up 26% from FY 2019). Profit margin: 32% (down from 35% in FY 2019). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has increased by 38% per year, which means it is tracking significantly ahead of earnings growth.Reported Earnings • Mar 11Full year 2020 earnings released: EPS CN¥0.88 (vs CN¥0.70 in FY 2019)The company reported a solid full year result with improved earnings and revenues, although profit margins were weaker. Full year 2020 results: Revenue: CN¥5.02b (up 36% from FY 2019). Net income: CN¥1.60b (up 25% from FY 2019). Profit margin: 32% (down from 35% in FY 2019). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has increased by 38% per year, which means it is tracking significantly ahead of earnings growth.Analyst Estimate Surprise Post Earnings • Mar 11Revenue beats expectationsRevenue exceeded analyst estimates by 6.3%. Over the next year, revenue is forecast to grow 9.6%, compared to a 61% growth forecast for the Biotechs industry in China.Valuation Update With 7 Day Price Move • Feb 11Investor sentiment improved over the past weekAfter last week's 17% share price gain to CN¥53.98, the stock is trading at a trailing P/E ratio of 76.7x, up from the previous P/E ratio of 65.5x. This compares to an average P/E of 70x in the Biotechs industry in China. Total returns to shareholders over the past three years are 323%.Is New 90 Day High Low • Feb 11New 90-day high: CN¥53.98The company is up 21% from its price of CN¥44.63 on 13 November 2020. The Chinese market is up 9.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 20% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥45.10 per share.Valuation Update With 7 Day Price Move • Jan 12Investor sentiment improved over the past weekAfter last week's 16% share price gain to CN¥52.97, the stock is trading at a trailing P/E ratio of 75.3x, up from the previous P/E ratio of 64.9x. This compares to an average P/E of 64x in the Biotechs industry in China. Total returns to shareholders over the past three years are 284%.Valuation Update With 7 Day Price Move • Jan 08Investor sentiment improved over the past weekAfter last week's 19% share price gain to CN¥50.39, the stock is trading at a trailing P/E ratio of 71.6x, up from the previous P/E ratio of 60x. This compares to an average P/E of 65x in the Biotechs industry in China. Total returns to shareholders over the past three years are 261%.Is New 90 Day High Low • Nov 03New 90-day low: CN¥46.08The company is down 34% from its price of CN¥70.17 on 05 August 2020. The Chinese market is down 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 20% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥23.11 per share.Reported Earnings • Nov 01Third quarter earnings releasedOver the last 12 months the company has reported total profits of CN¥1.28b, down 4.4% from the prior year. Total revenue was CN¥4.13b over the last 12 months, up 8.3% from the prior year.Analyst Estimate Surprise Post Earnings • Nov 01Third-quarter earnings released: Revenue beats expectationsThird-quarter revenue exceeded analyst estimates by 14% at CN¥1.69b. Revenue is forecast to grow 26% over the next year, compared to a 41% growth forecast for the Biotechs industry in China.Valuation Update With 7 Day Price Move • Oct 24Market pulls back on stock over the past weekAfter last week's 15% share price decline to CN¥51.27, the stock is trading at a trailing P/E ratio of 72.6x, down from the previous P/E ratio of 85.5x. This compares to an average P/E of 74x in the Biotechs industry in China. Total returns to shareholders over the past three years are 251%.이익 및 매출 성장 예측XSEC:002007 - 애널리스트 향후 추정치 및 과거 재무 데이터 (CNY Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수12/31/20285,5001,3938622,279512/31/20275,1301,2005,406789612/31/20264,52093914184233/31/20264,490858676857N/A12/31/20254,595940681878N/A9/30/20254,2679491,1041,050N/A6/30/20254,5251,164861969N/A3/31/20254,4591,1398101,023N/A12/31/20244,3791,0888041,059N/A9/30/20244,9201,3384361,113N/A6/30/20245,4091,395256900N/A3/31/20245,2491,3923461,027N/A12/31/20235,3421,4825921,346N/A9/30/20234,8281,2438071,538N/A6/30/20233,7531,0201,0991,713N/A3/31/20234,7571,1948351,268N/A1/1/20234,5171,076563957N/A9/30/20224,6771,139136662N/A6/30/20225,4971,42554704N/A3/31/20224,4531,2774741,225N/A1/1/20224,4361,2996211,432N/A9/30/20215,3111,7091,0161,642N/A6/30/20214,9251,5599071,594N/A3/31/20214,9691,6217641,495N/A12/31/20205,0231,6137041,325N/A9/30/20204,1341,2846081,166N/A6/30/20203,6841,2889021,295N/A3/31/20203,6821,2719531,271N/A12/31/20193,7001,283N/A1,363N/A9/30/20193,8191,344N/A1,334N/A6/30/20193,4181,194N/A1,451N/A3/31/20193,3511,192N/A1,440N/A12/31/20183,2171,140N/A1,293N/A9/30/20182,738961N/A864N/A6/30/20182,556843N/A590N/A3/31/20182,392773N/A308N/A12/31/20172,368821N/A177N/A9/30/20172,195792N/A146N/A6/30/20172,091801N/A120N/A3/31/20172,061843N/A203N/A12/31/20161,935780N/A330N/A9/30/20161,767737N/A443N/A6/30/20161,671690N/A585N/A3/31/20161,585632N/A549N/A12/31/20151,472589N/A549N/A9/30/20151,386575N/A501N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: 002007 의 연간 예상 수익 증가율(18.1%)이 saving rate(2.4%)보다 높습니다.수익 vs 시장: 002007 의 연간 수익(18.1%)이 CN 시장(26.1%)보다 느리게 성장할 것으로 예상됩니다.고성장 수익: 002007 의 수입은 증가할 것으로 예상되지만 상당히 증가하지는 않을 것입니다.수익 대 시장: 002007 의 수익(연간 7.8%)이 CN 시장(연간 16.1%)보다 느리게 성장할 것으로 예상됩니다.고성장 매출: 002007 의 수익(연간 7.8%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: 002007의 자본 수익률은 3년 후 9.7%로 낮을 것으로 예상됩니다.성장 기업 찾아보기7D1Y7D1Y7D1YPharmaceuticals-biotech 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/07/23 22:22종가2026/07/23 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Hualan Biological Engineering Inc.는 20명의 분석가가 다루고 있습니다. 이 중 6명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Ethan CuiBofA Global ResearchFusheng CheungChina Galaxy International Securities (Hong Kong)Fang QuanChina International Capital Corporation Limited17명의 분석가 더 보기
공고 • Jun 30Hualan Biological Engineering Inc. to Report First Half, 2026 Results on Aug 29, 2026Hualan Biological Engineering Inc. announced that they will report first half, 2026 results on Aug 29, 2026
Declared Dividend • Jun 11Dividend of CN¥0.50 announcedShareholders will receive a dividend of CN¥0.50. Ex-date: 15th June 2026 Payment date: 15th June 2026 Dividend yield will be 7.6%, which is higher than the industry average of 1.6%. Sustainability & Growth Dividend is not covered by earnings (213% earnings payout ratio) nor is it covered by cash flows (270% cash payout ratio). The dividend has increased by an average of 23% per year over the past 10 years. However, payments have been volatile during that time. The company's earnings per share (EPS) would need to grow by 137% to bring the payout ratio under control. EPS is expected to grow by 65% over the next 3 years, which means the dividend may need to be reduced to reach a sustainable payout ratio.
공고 • Jun 10Hualan Biological Engineering Inc. Announces 2025 Final Profit Distribution Plan to Be Implemented (A Shares), Payable on 15 June 2026Hualan Biological Engineering Inc. announced 2025 final profit distribution plan to be implemented (A shares) of CNY 5.00000000 per 10 shares(tax included). Record date: 12 June 2026, Ex-date: 15 June 2026, Payment date: 15 June 2026.
Board Change • May 20Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was an independent director. The company's board is composed of: 1 new director. 6 experienced directors. 5 highly experienced directors. 3 independent directors (6 non-independent directors). Independent Director Zhiqian Zhang was the last independent director to join the board, commencing their role in 2025. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
공고 • Mar 31Hualan Biological Engineering Inc. to Report Q1, 2026 Results on Apr 27, 2026Hualan Biological Engineering Inc. announced that they will report Q1, 2026 results on Apr 27, 2026
공고 • Mar 28Hualan Biological Engineering Inc., Annual General Meeting, Apr 20, 2026Hualan Biological Engineering Inc., Annual General Meeting, Apr 20, 2026, at 14:30 China Standard Time. Location: The Company's Meeting Room, Xinxiang, Henan China
공고 • Dec 31Hualan Biological Engineering Inc. to Report Fiscal Year 2025 Results on Mar 28, 2026Hualan Biological Engineering Inc. announced that they will report fiscal year 2025 results on Mar 28, 2026
공고 • Sep 30Hualan Biological Engineering Inc. to Report Q3, 2025 Results on Oct 30, 2025Hualan Biological Engineering Inc. announced that they will report Q3, 2025 results on Oct 30, 2025
공고 • Sep 24Hualan Biological Engineering Inc. Approves Interim Dividend for 2025Hualan Biological Engineering Inc. held its 2nd Extraordinary General Meeting of 2025 on 22 September 2025, approved interim Cash dividend/10 shares (tax included): CNY5.00000000 for 2025.
공고 • Aug 29Hualan Biological Engineering Inc. Proposes Interim Cash Dividend for 2025Hualan Biological Engineering Inc. at its EGM to be held on September 22, 2025, proposed the detailed profit distribution plan are as follows: Cash dividend/10 shares (tax included): CNY5.00000000.
공고 • Jul 02Hualan Biological Engineering Inc. to Report First Half, 2025 Results on Aug 29, 2025Hualan Biological Engineering Inc. announced that they will report first half, 2025 results on Aug 29, 2025
공고 • Apr 01Hualan Biological Engineering Inc. Proposes Final Cash Dividend for the Year 2024Hualan Biological Engineering Inc. announced on 31 March 2025 the profit distribution proposal for the year 2024 as final cash dividend/10 shares (tax included) of CNY 2.00000000.
공고 • Mar 31Hualan Biological Engineering Inc. to Report Q1, 2025 Results on Apr 28, 2025Hualan Biological Engineering Inc. announced that they will report Q1, 2025 results on Apr 28, 2025
공고 • Mar 29Hualan Biological Engineering Inc., Annual General Meeting, Apr 25, 2025Hualan Biological Engineering Inc., Annual General Meeting, Apr 25, 2025, at 14:30 China Standard Time. Location: The Company's Meeting Room, Xinxiang, Henan China
공고 • Dec 31Hualan Biological Engineering Inc. to Report Fiscal Year 2024 Results on Mar 29, 2025Hualan Biological Engineering Inc. announced that they will report fiscal year 2024 results on Mar 29, 2025
Reported Earnings • Oct 30Third quarter 2024 earnings released: EPS: CN¥0.27 (vs CN¥0.30 in 3Q 2023)Third quarter 2024 results: EPS: CN¥0.27 (down from CN¥0.30 in 3Q 2023). Revenue: CN¥1.84b (down 21% from 3Q 2023). Net income: CN¥483.5m (down 11% from 3Q 2023). Profit margin: 26% (up from 23% in 3Q 2023). The increase in margin was driven by lower expenses. Revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 26% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has fallen by 19% per year, which means it is performing significantly worse than earnings.
공고 • Sep 30Hualan Biological Engineering Inc. to Report Q3, 2024 Results on Oct 31, 2024Hualan Biological Engineering Inc. announced that they will report Q3, 2024 results on Oct 31, 2024
Valuation Update With 7 Day Price Move • Sep 27Investor sentiment improves as stock rises 16%After last week's 16% share price gain to CN¥16.41, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 21x in the Biotechs industry in China. Total loss to shareholders of 39% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥27.89 per share.
Reported Earnings • Aug 30Second quarter 2024 earnings released: EPS: CN¥0.098 (vs CN¥0.096 in 2Q 2023)Second quarter 2024 results: EPS: CN¥0.098 (up from CN¥0.096 in 2Q 2023). Revenue: CN¥865.4m (up 23% from 2Q 2023). Net income: CN¥178.4m (up 2.0% from 2Q 2023). Profit margin: 21% (down from 25% in 2Q 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 24% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has fallen by 20% per year, which means it is performing significantly worse than earnings.
공고 • Jun 29Hualan Biological Engineering Inc. to Report First Half, 2024 Results on Aug 30, 2024Hualan Biological Engineering Inc. announced that they will report first half, 2024 results on Aug 30, 2024
Declared Dividend • Jun 08Dividend of CN¥0.30 announcedDividend of CN¥0.30 is the same as last year. Ex-date: 14th June 2024 Payment date: 14th June 2024 Dividend yield will be 1.7%, which is about the same as the industry average. Sustainability & Growth Dividend is covered by earnings (39% earnings payout ratio) but not covered by cash flows (159% cash payout ratio). The dividend has increased by an average of 25% per year over the past 10 years. However, payments have been volatile during that time. EPS is expected to grow by 62% over the next 3 years, which should provide support to the dividend and adequate earnings cover.
공고 • Jun 08Hualan Biological Engineering Inc. Announces Final Profit Distribution Plan to Be Implemented on A Shares for the Year 2023, Payable on 14 June 2024Hualan Biological Engineering Inc. announced final profit distribution plan to be implemented on A shares as cash dividend per ten shares (tax included) of CNY 3.00000000 for the year 2023, payable on 14 June 2024. Record date: 13 June 2024. Ex-date: 14 June 2024.
Reported Earnings • Apr 26First quarter 2024 earnings released: EPS: CN¥0.14 (vs CN¥0.19 in 1Q 2023)First quarter 2024 results: EPS: CN¥0.14 (down from CN¥0.19 in 1Q 2023). Revenue: CN¥787.3m (down 11% from 1Q 2023). Net income: CN¥261.8m (down 26% from 1Q 2023). Profit margin: 33% (down from 40% in 1Q 2023). Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has fallen by 23% per year, which means it is performing significantly worse than earnings.
Reported Earnings • Apr 01Full year 2023 earnings released: EPS: CN¥0.81 (vs CN¥0.59 in FY 2022)Full year 2023 results: EPS: CN¥0.81 (up from CN¥0.59 in FY 2022). Revenue: CN¥5.34b (up 18% from FY 2022). Net income: CN¥1.48b (up 38% from FY 2022). Profit margin: 28% (up from 24% in FY 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 25% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has fallen by 11% per year but the company’s share price has fallen by 21% per year, which means it is performing significantly worse than earnings.
공고 • Mar 30Hualan Biological Engineering Inc. to Report Q1, 2024 Results on Apr 26, 2024Hualan Biological Engineering Inc. announced that they will report Q1, 2024 results on Apr 26, 2024
공고 • Dec 30Hualan Biological Engineering Inc. to Report Fiscal Year 2023 Results on Mar 30, 2024Hualan Biological Engineering Inc. announced that they will report fiscal year 2023 results on Mar 30, 2024
Reported Earnings • Nov 01Third quarter 2023 earnings released: EPS: CN¥0.30 (vs CN¥0.17 in 3Q 2022)Third quarter 2023 results: EPS: CN¥0.30 (up from CN¥0.17 in 3Q 2022). Revenue: CN¥2.33b (up 86% from 3Q 2022). Net income: CN¥540.6m (up 70% from 3Q 2022). Profit margin: 23% (down from 25% in 3Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 24% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has fallen by 12% per year but the company’s share price has fallen by 20% per year, which means it is performing significantly worse than earnings.
Reported Earnings • Aug 24Second quarter 2023 earnings released: EPS: CN¥0.096 (vs CN¥0.19 in 2Q 2022)Second quarter 2023 results: EPS: CN¥0.096 (down from CN¥0.19 in 2Q 2022). Revenue: CN¥704.6m (down 59% from 2Q 2022). Net income: CN¥175.0m (down 50% from 2Q 2022). Profit margin: 25% (up from 20% in 2Q 2022). The increase in margin was driven by lower expenses. Revenue is forecast to grow 23% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has fallen by 11% per year but the company’s share price has fallen by 29% per year, which means it is performing significantly worse than earnings.
공고 • Jun 08Hualan Biological Engineering Inc. Announces Final Dividend on Share A for 2022, Payable on June 14, 2023Hualan Biological Engineering Inc. announced final Cash dividend/10 shares (tax included): CNY 3.00000000 on share A for 2022. Record date: 13 June 2023, Ex-date: 14 June 2023, Payment date: 14 June 2023.
Reported Earnings • Mar 30Full year 2022 earnings released: EPS: CN¥0.59 (vs CN¥0.71 in FY 2021)Full year 2022 results: EPS: CN¥0.59 (down from CN¥0.71 in FY 2021). Revenue: CN¥4.52b (up 1.8% from FY 2021). Net income: CN¥1.08b (down 17% from FY 2021). Profit margin: 24% (down from 29% in FY 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 20% p.a. on average during the next 2 years, compared to a 24% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has fallen by 17% per year, which means it is performing significantly worse than earnings.
Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Director Yunlong Wang was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Oct 31Third quarter 2022 earnings released: EPS: CN¥0.17 (vs CN¥0.33 in 3Q 2021)Third quarter 2022 results: EPS: CN¥0.17 (down from CN¥0.33 in 3Q 2021). Revenue: CN¥1.25b (down 40% from 3Q 2021). Net income: CN¥317.6m (down 47% from 3Q 2021). Profit margin: 25% (down from 29% in 3Q 2021). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has remained flat but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings.
Reported Earnings • Aug 24Second quarter 2022 earnings released: EPS: CN¥0.19 (vs CN¥0.11 in 2Q 2021)Second quarter 2022 results: EPS: CN¥0.19 (up from CN¥0.11 in 2Q 2021). Revenue: CN¥1.71b (up 157% from 2Q 2021). Net income: CN¥349.1m (up 71% from 2Q 2021). Profit margin: 20% (down from 31% in 2Q 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to stay flat compared to a 34% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings.
Valuation Update With 7 Day Price Move • Jun 21Investor sentiment improved over the past weekAfter last week's 19% share price gain to CN¥22.86, the stock trades at a forward P/E ratio of 26x. Average forward P/E is 30x in the Biotechs industry in China. Total returns to shareholders of 4.1% over the past three years.
Board Change • May 25Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Director Yunlong Wang was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Apr 01Full year 2021 earnings released: EPS: CN¥0.71 (vs CN¥0.89 in FY 2020)Full year 2021 results: EPS: CN¥0.71 (down from CN¥0.89 in FY 2020). Revenue: CN¥4.44b (down 12% from FY 2020). Net income: CN¥1.30b (down 20% from FY 2020). Profit margin: 29% (down from 32% in FY 2020). The decrease in margin was driven by lower revenue. Over the next year, revenue is forecast to grow 9.4%, compared to a 51% growth forecast for the pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings.
Valuation Update With 7 Day Price Move • Sep 08Investor sentiment deteriorated over the past weekAfter last week's 15% share price decline to CN¥30.13, the stock trades at a forward P/E ratio of 32x. Average forward P/E is 36x in the Biotechs industry in China. Total returns to shareholders of 71% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥17.49 per share.
Reported Earnings • Aug 30Second quarter 2021 earnings released: EPS CN¥0.11 (vs CN¥0.14 in 2Q 2020)The company reported a poor second quarter result with weaker earnings, revenues and profit margins. Second quarter 2021 results: Revenue: CN¥665.2m (down 6.2% from 2Q 2020). Net income: CN¥204.5m (down 23% from 2Q 2020). Profit margin: 31% (down from 37% in 2Q 2020). The decrease in margin was primarily driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 17% per year whereas the company’s share price has increased by 21% per year.
Reported Earnings • May 02First quarter 2021 earnings released: EPS CN¥0.14 (vs CN¥0.14 in 1Q 2020)The company reported a decent first quarter result with improved earnings and profit margins, although revenues were weaker. First quarter 2021 results: Revenue: CN¥623.4m (down 8.0% from 1Q 2020). Net income: CN¥252.8m (up 2.2% from 1Q 2020). Profit margin: 41% (up from 37% in 1Q 2020). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has increased by 40% per year, which means it is tracking significantly ahead of earnings growth.
Reported Earnings • Mar 31Full year 2020 earnings released: EPS CN¥0.89 (vs CN¥0.71 in FY 2019)The company reported a solid full year result with improved earnings and revenues, although profit margins were weaker. Full year 2020 results: Revenue: CN¥5.02b (up 36% from FY 2019). Net income: CN¥1.61b (up 26% from FY 2019). Profit margin: 32% (down from 35% in FY 2019). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has increased by 38% per year, which means it is tracking significantly ahead of earnings growth.
Reported Earnings • Mar 11Full year 2020 earnings released: EPS CN¥0.88 (vs CN¥0.70 in FY 2019)The company reported a solid full year result with improved earnings and revenues, although profit margins were weaker. Full year 2020 results: Revenue: CN¥5.02b (up 36% from FY 2019). Net income: CN¥1.60b (up 25% from FY 2019). Profit margin: 32% (down from 35% in FY 2019). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has increased by 38% per year, which means it is tracking significantly ahead of earnings growth.
Analyst Estimate Surprise Post Earnings • Mar 11Revenue beats expectationsRevenue exceeded analyst estimates by 6.3%. Over the next year, revenue is forecast to grow 9.6%, compared to a 61% growth forecast for the Biotechs industry in China.
Valuation Update With 7 Day Price Move • Feb 11Investor sentiment improved over the past weekAfter last week's 17% share price gain to CN¥53.98, the stock is trading at a trailing P/E ratio of 76.7x, up from the previous P/E ratio of 65.5x. This compares to an average P/E of 70x in the Biotechs industry in China. Total returns to shareholders over the past three years are 323%.
Is New 90 Day High Low • Feb 11New 90-day high: CN¥53.98The company is up 21% from its price of CN¥44.63 on 13 November 2020. The Chinese market is up 9.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 20% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥45.10 per share.
Valuation Update With 7 Day Price Move • Jan 12Investor sentiment improved over the past weekAfter last week's 16% share price gain to CN¥52.97, the stock is trading at a trailing P/E ratio of 75.3x, up from the previous P/E ratio of 64.9x. This compares to an average P/E of 64x in the Biotechs industry in China. Total returns to shareholders over the past three years are 284%.
Valuation Update With 7 Day Price Move • Jan 08Investor sentiment improved over the past weekAfter last week's 19% share price gain to CN¥50.39, the stock is trading at a trailing P/E ratio of 71.6x, up from the previous P/E ratio of 60x. This compares to an average P/E of 65x in the Biotechs industry in China. Total returns to shareholders over the past three years are 261%.
Is New 90 Day High Low • Nov 03New 90-day low: CN¥46.08The company is down 34% from its price of CN¥70.17 on 05 August 2020. The Chinese market is down 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 20% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥23.11 per share.
Reported Earnings • Nov 01Third quarter earnings releasedOver the last 12 months the company has reported total profits of CN¥1.28b, down 4.4% from the prior year. Total revenue was CN¥4.13b over the last 12 months, up 8.3% from the prior year.
Analyst Estimate Surprise Post Earnings • Nov 01Third-quarter earnings released: Revenue beats expectationsThird-quarter revenue exceeded analyst estimates by 14% at CN¥1.69b. Revenue is forecast to grow 26% over the next year, compared to a 41% growth forecast for the Biotechs industry in China.
Valuation Update With 7 Day Price Move • Oct 24Market pulls back on stock over the past weekAfter last week's 15% share price decline to CN¥51.27, the stock is trading at a trailing P/E ratio of 72.6x, down from the previous P/E ratio of 85.5x. This compares to an average P/E of 74x in the Biotechs industry in China. Total returns to shareholders over the past three years are 251%.